This is the first study to investigate the efficacy and safety of emicizumab prophylaxis in adults and adolescents with hemophilia A, both with and without FVIII inhibitors in Bangladesh, a lower middle‐income country where only 5.5% of hemophilia A patients receive prophylactic treatment and most of the patients cannot afford standard treatment and are receiving inadequate on‐demand therapy for hemophilia A [24]. This evidence concerns the gene F8 and hemophilia A.